Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m² plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients

References

• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Schouten H C, Qian W, Kualoy S, Porcellini A, Hagberg H, Johnssen H E, et al. High dose therapy improves progression free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized CUP trial. J Clin Oncol 2003; 21: 3918–3927
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch D C, Dreger P, Goldstone A H, Boogaerts M A, Ferrant A, et al. Randomised trial of filgrastim—mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357
   PubMed Web of Science ®Google Scholar
• Russell N H, McQuaker G, Stainer C, Byrne J L, Haynes A P. Stem cell mobilisation in lymphoproliferative disease. Bone Marrow Transplant 1998; 22: 935–940
   PubMed Web of Science ®Google Scholar
• Jantunen E, Putkonen M, Nousiainen T, Pelliniemi T-T, Mahalamaki E, Remes K. Low dose or intermediate dose cyclophosphamide plus granulocyte-colony stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–351
   PubMed Web of Science ®Google Scholar
• Fitoussi O, Perrau V, Boiron J M, Bouzigon E, Cony-Makhoul P, Pigneux A, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837–842
   PubMed Web of Science ®Google Scholar
• Lefrere F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F, et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 mg/kg is as effective and less toxic than high-dose cyclophosphamide plus G-CSF dose of 5 µg/kg for progenitor cell mobilization: results from a monocentric study in 82 patients. Bone Marrow Transplant 2006; 37: 725–729
   PubMed Web of Science ®Google Scholar
• Lee J L, Kim S, Kim S W, Kim E K, Kim S B, Kang Y K, et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005; 35: 449–454
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Callander N, Freytes C O, Shaughness P, Liu Q, Tsai T W, et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequencial GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized study. J Hematother Stem Cell Res 2000; 9: 737–748
   PubMedGoogle Scholar
• Goldschmidt H, Hegenbart U, Haas R, Hunstein W, et al. Mobilisation of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691–697
   PubMed Web of Science ®Google Scholar
• Copelan E A, Ceselski S K, Ezzone S A, Lasky L C, Penza S L, Bechtel T P, et al. Mobilization of peripheral blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1997; 15: 759–765
   PubMed Web of Science ®Google Scholar
• Kanfer E J, Mc Guigan D, Samson D, Abboudi Z, Abrahamson G, Apperley J F, et al. High dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. Br J Cancer 1998; 78: 928–932
   PubMed Web of Science ®Google Scholar
• Junghanss C, Leithauser M, Wilhelm S, Kleine H D, Knopp A, Decker S, et al. High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize. Ann Hematol 2001; 80: 96–102
   PubMed Web of Science ®Google Scholar
• Raiser M, Josting A, Draube A, Mapara M Y, Scheld C, Chemnitz J, et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed mobilization. Bone Marrow Transplant 1999; 23: 1223–1228
   PubMed Web of Science ®Google Scholar
• Bolwell B J, Kalaycio M, Sobecks R, Andresen S, Kuczkowski E, Bernhard L, et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 2002; 30: 587–591
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Marie J P, Delforge A, Socquet M, Thevenin D, Zittoun R, et al. Comparison of in vitro inhibition of (VP-16) on leukemic and normal myeloid, erithroid clonogenic cells. Exp Hematol 1989; 17: 843–846
   PubMed Web of Science ®Google Scholar
• Milone G, Leotta S, Indelicato F, Mercurio S, Moschetti G, Di Raimondo F, et al. G-CSF alone versus cyclophopsphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pre-treatment. Bone Marrow Transplant 2003; 31: 747–754
   PubMed Web of Science ®Google Scholar
• Watts M J, Sullivan A M, Jamieson E, Pearce R, Fielding A, Devereux S, et al. Progenitor-cell mobilization after low dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–546
   PubMed Web of Science ®Google Scholar
• Chopra M W, McMillan A, Pearce R, Linch D C, Goldstone A H. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's Lymphoma. J Clin Oncol 1995; 13: 588–595
   PubMed Web of Science ®Google Scholar
• Donnelly J P, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw B E. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992; 9: 409–413
   PubMed Web of Science ®Google Scholar
• Mc Quaker I G, Haynes A P, Stainer C, Russel N H. Mobilization of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant 1999; 24: 715–722
   PubMed Web of Science ®Google Scholar
• Watts M J, Ings S J, Leverett D, MacMillan A, Devereux S, Goldstone A H, et al. ESHAP and G-CSF is superior blood stem cells mobilizing regimen compared to cyclophosphamide 1.5 g/m2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 8: 278–282
   Web of Science ®Google Scholar
• Goldberg M A, Antin J H, Guinan E C, Rappeport J M. Cyclophosphamide cardiotoxicity: analysis of dosing as a risk factor. Blood 1986; 5: 1114–1118
   Google Scholar
• Lieberg C F, Rausing A, Langeland P. Cyclophosphamide hemorragic cystitis. Scand J Urol Nephrol 1970; 4: 183–190
   PubMedGoogle Scholar
• Rosenfeld C S, Shadduck R K, Zeigler Z R, Andrews F, Nemunaitis J. Cyclophosphamide-mobilized peripheral blood stem cells in patients with lymphoid malignancies. Bone Marrow Transplant 1995; 15: 433–438
   PubMed Web of Science ®Google Scholar
• Avery R K, Pohlman B L, Mossad S B, Goormastic M, Longworth D L, Kalaycio M E, et al. The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose Etoposide (VP-16) for stem cell mobilization. Bone Marrow Transplant 2002; 30: 311–314
   PubMed Web of Science ®Google Scholar
• Molle P, Pereira D, Nagy T, Song K, Saragosa R, Keating A, et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cell for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplantation 2002; 30: 273–278
   PubMed Web of Science ®Google Scholar
• Boeve S, Strupeck J, Creech S, Stiff P J. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997–1003
   PubMed Web of Science ®Google Scholar
• Jindra P, Koza V, Lysak D, Vozobulova V, Steinerova K. Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF. Bone Marrow Transplant 2005; 35: 729–730
   PubMed Web of Science ®Google Scholar
• Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 464–474
   Web of Science ®Google Scholar
• Andre M, Baudoux E, Bron D, D'Hondt V, Fassotte M-F, D'Hondt L, et al. Phase III randomized study comparing 5 or 10 µg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patient with nonmyeloid malignancies. Transfusion 2003; 43: 50–57
   PubMed Web of Science ®Google Scholar
• Damon L, Rugo H, Tolaney S, Navarro M, Martin T, Ries C, et al. Cytoreduction of lymphoid malignancies and mobilizations of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant 2006; 12: 316–324
   PubMed Web of Science ®Google Scholar
• Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options in follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol 2006; 133: 3–18
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Philip P. Balanced translocation involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991; 78: 1147–1148
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak M L, Arber D A, Niland J C, Nademanee A, et al. Predictors of therapy-related leukaemia and myelodyslasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593
   PubMed Web of Science ®Google Scholar
• Copelan E, Hoshaw-Woodard S, Elder P, Penza S, Farag S, Marcucci G, et al. Therapy related myelodisplasia and leukaemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. Bone Marrow Transplant 2004; 34: 85–87
   PubMed Web of Science ®Google Scholar
• Metayer C, Curtis R E, Vose J, Sobocinski K, Horowitz M M, Bhatia S, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case – control study. Blood 2003; 101: 2015–2023
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Beyer J, Droz J P, Harstrick A, Hartmann J T, Biron P, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386–3391
   PubMed Web of Science ®Google Scholar
• Le Deley M C, Le Blanc T, Shamsaldin A, Raquin M A, Lacour B, Sommelet D, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case control study by the société francaise d'oncologie pediatrique. J Clin Oncol 2003; 21: 1074–1081
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Andersen M K, Christiansen D H. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95: 3273–3279
   PubMed Web of Science ®Google Scholar
• Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak M L, Chang K L, et al. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol 2005; 23: 6699
   PubMed Web of Science ®Google Scholar